Homepage > Company > Media > Pharma News > 2019 > Glaxo To Invest USD100 Million In US Vaccine Manufacturing Site

Glaxo To Invest USD100 Million In US Vaccine Manufacturing Site

LONDON (Alliance News) - GlaxoSmithKline PLC said on Wednesday it will invest USD100 million in its manufacturing site in Montana, US, to expand long-term vaccine manufacturing capabilities.

In particular, the FTSE 100 pharmaceutical firm plans to expand the production capacity of key components of the adjuvant system, which is used for several of Glaxo's vaccines for malaria and shingles.

"For more than a decade, our Hamilton facility has supported GSK's adjuvant system development program. By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including Shingrix," said Glaxo US Pharmaceuticals President Jack Bailey.

Shares in GlaxoSmithKline were down 0.9% at 1,543.40 pence on Wednesday afternoon.

25 April, 2019

http://www.morningstar.co.uk/uk/news/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...